Key Highlights

  • Neurocrine Biosciences (NASDAQ:NBIX) gained 13.42% on November 3, 2026, after third-quarter Revenue climbed 41% to USD 1,123 million from USD 795 million.
  • Ingrezza net sales reached USD 801 million, up 17% from USD 687 million, and 2026 Ingrezza guidance was lifted to USD 2,900 million to USD 2,925 million from USD 2,825 million to USD 2,875 million.
  • Crenessity net sales were USD 211 million, up 115% from USD 98 million a year earlier, as the congenital adrenal hyperplasia treatment continues to launch.
  • Non-GAAP diluted Earnings were USD 3.29 a share, up from USD 2.17, while GAAP diluted earnings were USD 1.96, down from USD 2.04 a year earlier.

The Quarter in Brief

Neurocrine Biosciences reported third-quarter 2026 results for the period ended September 30. Total revenue was USD 1,123 million, up 41%. Ingrezza, prescribed for tardive dyskinesia and chorea in Huntington's disease, generated USD 801 million of net sales, up 17%. Crenessity, approved for classic congenital adrenal hyperplasia, a genetic disorder of the adrenal glands, brought in USD 211 million, up 115%. Non-GAAP diluted earnings were USD 3.29 a share against USD 2.17, while GAAP earnings came to USD 1.96 against USD 2.04. The shares closed 13.42% higher on November 3, 2026, according to published market data. Ingrezza made up about 71% of revenue and Crenessity about 19%, simple arithmetic, leaving about USD 111 million from other sources. Non-GAAP earnings rose about 52%, simple arithmetic, faster than revenue, which points to Operating Leverage on a larger sales base at Neurocrine Biosciences (NASDAQ:NBIX).

Why the Guidance Change Matters

Guidance resets the base on which investors value a drug maker. Neurocrine lifted its 2026 Ingrezza net sales range to USD 2,900 million to USD 2,925 million from USD 2,825 million to USD 2,875 million, a midpoint rise of about USD 62.5 million, simple arithmetic. The release gives no 2026 range for Crenessity, so investors must estimate its launch curve themselves. The gap between non-GAAP and GAAP earnings, USD 1.33 a share this quarter, simple arithmetic, reflects items such as Stock Compensation and other adjustments, so the cleaner comparison with consensus depends on which basis analysts use. The raise also signals that Ingrezza Demand held up through the third quarter despite its larger base.

Risks and Signals to Track

Ingrezza growth of 17% trails the company-wide 41%, and the drug faces payer pricing pressure and the prospect of competition. Crenessity serves a small patient population, so launch growth can slow once early patients are treated. GAAP earnings fell year over year even as revenue rose, which shows costs are climbing. A 13.4% one-day gain also raises the bar for the next report, and reliance on two products means a setback in either would matter. Investors will watch Crenessity prescriptions, Ingrezza demand, research spending and any pipeline readouts. The release gave no 2026 Crenessity range, so analysts will lean on quarterly trends, and a surprise either way could move the shares sharply again.

Where Things Stand

Neurocrine rose 13.4% because it beat on revenue growth, raised Ingrezza guidance and showed Crenessity scaling quickly. Growth rests on two drugs, and GAAP earnings were lower than a year ago, so the picture is strong but not risk-free. For Neurocrine Biosciences (NASDAQ:NBIX), the next catalysts are Crenessity launch data and any pricing changes affecting Ingrezza. Large one-day gains can fade. Nothing here is Investment advice or a price forecast.